Novartis buys radiopharmaceuticals company Endocyte for $2.1bn
Novartis AG agreed to acquire public radiopharmaceuticals firm Endocyte Inc. (targeted cancer therapies and companion imaging agents) for $24 in cash per share (a 55% premium), for an equity value of $2.1bn (an enterprise value of $1.9bn, taking into account the company's cash on its balance sheet).
- In Vitro Diagnostics
- Drug Delivery
- Radiopharmaceuticals, Contrast Agents
- Diagnostic Imaging Equipment & Supplies
- Full Acquisition
- Includes Contract
- Payment Includes Cash
Please contact Sales at: (212) 520-2765 or email [email protected]
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.